Skip to content
The Great News – Lifestyle
Home
Sample Page
Author:
Resolve Therapeutics, LLC
Resolve Therapeutics Completes Enrollment in Phase 2 Study of RSLV-132 in Sjögren’s Disease
October 7, 2026